Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...
Addition joins a growing list of launches this year, following in the footsteps of startups like Crystalys Therapeutics and ...
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s ...
For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...
San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback